文献速递认知障碍与痴呆

血浆NT1 Tau是阿尔茨海默病的特异性早期标志物

Plasma NT1 Tau is a Specific and Early Marker of Alzheimer's Disease.
PubMed 文献 · Ann Neurol · 2020-09-25

研究评估了自建NT1检测法测定的血浆Tau在阿尔茨海默病(AD)中的特异性及预测价值。结果显示,血浆NT1 Tau在AD中特异性升高,而在非AD痴呆中不升高;在主观认知下降(SCD)或轻度认知障碍(MCI)患者中,基线NT1 Tau升高可预测进展为AD痴呆,且优于Quanterix和Roche检测法。

要点

  • 血浆NT1 Tau在AD中特异性升高,非AD痴呆中不升高。
  • 基线NT1 Tau可预测SCD或MCI患者进展为AD痴呆。
  • NT1 Tau预测价值优于Quanterix和Roche检测法。

核心结论

  • 血浆NT1 Tau是AD的特异性标志物,在疾病早期即升高,可能作为初筛工具识别AD风险个体。

研究设计与样本

  • 研究纳入前瞻性随访的SCD或MCI患者(认知稳定、进展为AD痴呆或进展为非AD痴呆)及认知正常参与者,检测血浆NT1 Tau和NfL,并在基线SCD和MCI受试者中用Quanterix和Roche检测法测定Tau。

主要发现

  • 血浆NT1 Tau在AD中特异性升高,非AD痴呆中不升高;NfL在AD和非AD痴呆中均升高。
  • 基线NT1 Tau在进展为AD痴呆的SCD或MCI患者中升高,而Quanterix或Roche检测法测定的Tau未显示此升高。
  • 基线血浆NfL在进展为AD和非AD痴呆者中均升高。

临床怎么用

  • 血浆NT1 Tau可能作为初筛工具,识别SCD或MCI中进展为AD痴呆的高风险个体。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: There is an urgent need for sensitive, widely available, blood-based screening tests to identify presymptomatic individuals destined to develop Alzheimer's disease (AD). We investigated whether tau detected in plasma by our in-house NT1 assay is specifically altered in AD, and when applied to patients with subjective cognitive decline (SCD) or mild cognitive impairment (MCI) can serve to predict progression to AD dementia. The predictive value of NT1 versus tau measured using assays from Quanterix and Roche, and the specificity of NT1 for AD versus a nonspecific marker of neurodegeneration (neurofilament light [NfL]) were also examined. METHODS: NT1 tau and NfL were measured in plasma from prospectively followed patients with SCD or MCI who remained cognitively stable, converted to AD dementia, or converted to non-AD dementias, and in cognitively unimpaired participants. Tau was measured using Quanterix and Roche assays in baseline subjects with SCD and MCI. RESULTS: Plasma NT1 tau was specifically elevated in AD, but not in non-AD dementia compared with controls, whereas NfL was increased in both AD and non-AD dementias. Baseline specimens from individuals who had SCD or MCI revealed that NT1 tau, but not tau measured using Quanterix or Roche assays, is elevated in subjects who progress to AD dementia. As expected, baseline plasma NfL is elevated in those who progress to AD and non-AD dementias. INTERPRETATION: Plasma NT1 tau is a specific marker of AD, which is elevated early in disease and may prove useful as a first round screen to identify individuals at risk of developing AD. ANN NEUROL 2020;88:878-892.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Mengel D, Janelidze S, Glynn RJ, et al. Plasma NT1 Tau is a Specific and Early Marker of Alzheimer's Disease. Ann Neurol. 2020. PMID: 32829532. doi:10.1002/ana.25885

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。